QCDR Vendor ID,QCDR Organization Name,Measure ID,Measure Title,Measure Description,NQS Domain,Numerator,Denominator,Denominator Exclusions,Denominator Exceptions,Numerator Exclusion,Number of performance rates to be included in the XML,"Indicate an Overall Performance Rate if more than 1 performance rate is to be submitted Specify which rate will represent an overall performance rate for the measure or how an overall performance rate could be calculated based on the data submitted in the XML [for example, simple average of the performance rates submitted or weighted average (sum the numerators divided by the sum of the denominators), etc].",Measure Types,High Priority,Outcome,Inverse Measure (Y/N),Proportional Measure (Y/N),Continuous Variable Measure (Y/N),Ratio Measure (Y/N),Risk-Adjusted (Y/N)
6273354,"AAAAI American Academy of Allergy, Asthma, and Immunology Quality Clinical Data Registry Powered by Premier, Inc.",AAAAI2,Asthma: Assessment of Asthma Control â€“ Ambulatory Care Setting,Percentage of patients aged 5 years and older with a diagnosis of asthma who were evaluated at least once during the measurement period for asthma control (comprising asthma impairment and asthma risk). National Quality Strategy Domain: Effective Clinical Care Process Measure ,Effective Clinical Care,Patients who were evaluated at least once during the measurement period for asthma control.,All patients aged 5 years and older with a diagnosis of asthma. ,None,None,None,N/A,N/A,Process,,,N,Y,N,N,N
6273354,"AAAAI American Academy of Allergy, Asthma, and Immunology Quality Clinical Data Registry Powered by Premier, Inc.",AAAAI5,Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment,Percentage of patients aged 5 years and older who were assessed for IgE sensitivity to allergens prior to initiating allergen immunotherapy AND results documented in the medical record.National Quality Strategy Domain: Patient Safety Process Measure ,Patient Safety,Patients who were assessed and had documentation of IgE sensitivity to allergens in the allergen immunotherapy prescription prior to initiating allergen immunotherapy.,Patients aged 5 years and older who initiated allergen immunotherapy during the reporting period. ,None,None,None,N/A,N/A,Process,High Priority,,N,Y,N,N,N
